Skip to main content

Table 1 Clinical trials targeting CD24 registered with the National Clinical Trials Registry (NCT) system

From: Targeting CD24 as a novel immunotherapy for solid cancers

NCT ID

Phase

Treatment

Malignancy type

Enrollment

Endpoints

Locations

Current Status

NCT04060407

1b/2

CINDI

Metastatic Melanoma

0

Business Reasons

Huntsman Cancer Institute, Salt Lake City, Utah, USA

Withdrawn

NCT04552704

1/2

TIRAEC

Advanced Malignant Solid Neoplasm

3

Sponsor Change

University of California Davis Comprehensive Cancer Center

Sacramento, California, USA

Terminated

NCT04095858

3

CD24Fc/tacrolimus / methotrexate (CD24Fc/Tac/MTX)

Hematopoietic Stem Cell

Transplantation

Acute Graft Versus Host Disease

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Myelodysplastic Syndromes

11

Business Reasons

City of Hope (Site 0302), Duarte, California, USA

The University of Chicago Medical Center (Site 0306), Chicago, Illinois, USA

Penn State University Milton S. Hershey Medical Center (Site 0304), Hershey, Pennsylvania,

USA

Abramson Cancer Center of the University of Pennsylvania (Site 0309), Philadelphia, Pennsylvania, USA

Terminated

NCT02663622

2

Phase II Trial of CD24Fc for the Prevention of Acute GVHD Following Myeloablative Allogeneic HSCT (MK-7110–002)

Graft Versus Host Disease

Hematopoietic Stem Cell

Transplantation Leukemia

44

 

Indiana University School of Medicine, Indianapolis, Indiana, USA

The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA

Karmanos Cancer Institute,

Detroit, Michigan, USA

Ohio State University, Columbus, Ohio, USA

Completed

NCT01214512

Not Provided

Performance Evaluation of the Micromedic CD24 in Vitro Diagnostic Assay

Colorectal Cancer

229

Not Provided

Bat Yamon Gastroentrology Clinic, Bat Yam, Israel

Zamenhoff Gastroentrology Clinic, Tel Aviv, Israel

Completed

NCT01265225

Not Provided

Prognostic Value of Stem Cell Related Markers

Breast Cancer

0

No Finance

Baruch PMC, Poriya, Lower galilee, Israel

Withdrawn

NCT04907422

Not Provided

Diagnostic and Prognostic Accuracy of Gold Nanoparticles in Salivary Gland Tumours

Carcinoma Ex Pleomorphic

Adenoma of Salivary Glands

Pleomorphic

Adenoma of Salivary Glands

60

Not Provided

Faculty of Dentistry, October 6 University, Giza, Egypt

Completed

  1. Abbreviations: CINDI CD24Fc With Ipilimumab and Nivolumab to Decrease irAE, TIRAEC Treatment of Immune Related Adverse Events in Patients with CD24Fc, GVHD Graft Versus Host Disease